Albumin-bound formulation of paclitaxel (Abraxane^® ABI-007) in the treatment of breast cancer

Review

(4021) Views  (1342) Full article downloads

Authors: Evelina Miele, Gian Paolo Spinelli, Ermanno Miele, Federica Tomao, Silverio Tomao

Published Date April 2009 Volume 2009:4 Pages 99 - 105

DOI: http://dx.doi.org/10.2147/IJN.S3061

Evelina Miele¹, Gian Paolo Spinelli¹, Ermanno Miele², Federica Tomao¹, Silverio Tomao¹

¹Department of Experimental Medicine, University of Rome “Sapienza”, Rome, Italy; ²Biomedical Engineering, University of Rome Tor Vergata, Rome, Italy

Abstract: Breast cancer is the most common type of malignancy diagnosed in women. In the metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic molecular status. To overcome this poor water solubility, lipid-based solvents have been used as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-bound, 130-nm particle formulation of paclitaxel, free from any kind of solvent. It has been demonstrated to be superior to an equitoxic dose of standard paclitaxel with a significantly lower incidence of toxicities in a large, international, randomized phase III trial. The availability of new drugs, such as Abraxane^®, in association with other traditional and non-traditional drugs (new antineoplastic agents and targeted molecules), will give the oncologist many different effective treatment options for patients in this setting.

Keywords: paclitaxel, Abraxane, breast cancer, nanotechnology

Readers of this article also read: